Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MaaT Pharma
< Previous
1
2
Next >
MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux
January 27, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023
January 24, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting
December 11, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting
December 10, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
November 29, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
November 08, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
November 07, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
November 03, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology
October 04, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Publishes its Half Year Results and Provides a Business Overview
September 29, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September
September 08, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
July 28, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients
June 02, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022
May 24, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Reports Cash and Revenues for First Quarter 2022
May 05, 2022
From
MaaT Pharma
Via
Business Wire
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
April 21, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview
April 14, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors for Patients with Melanoma
April 07, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
April 04, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
March 28, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux
March 21, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting
March 17, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Reports Cash and Revenues for Full-Year 2021
February 28, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
February 08, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
January 24, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
January 17, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas
January 13, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
January 03, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
December 11, 2021
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
December 01, 2021
From
MaaT Pharma
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.